POINT试验:氯吡格雷疗效与CYP2C19等位基因状态的关系
结果显示基因型与治疗组之间无显著交互作用,未能重复CHANCE试验的发现。
要点
- 功能缺失等位基因携带者中,双联抗血小板治疗主要缺血事件风险未显著低于阿司匹林。
- 非携带者中双联治疗与阿司匹林的主要缺血事件风险差异同样无统计学意义。
- 基因型与主要缺血事件(P=0.36)及卒中(P=0.33)均无显著交互作用。
核心结论
- POINT试验本亚组未发现CYP2C19功能缺失携带状态与治疗组结局之间存在显著交互作用。
- 未能重复CHANCE试验结果,可能因所测功能缺失等位基因在此背景下临床意义有限,或两项试验种族构成不同。
- 两项试验差异也可能源于偶然,因本研究统计效能仅50%。
研究设计与样本
- POINT试验药物基因组学亚组研究,POINT共在10个国家269个中心入组患者,其中134个中心参与本亚组。
- 对DNA样本进行CYP2C19 *2、*3、*17等位基因分型,分为功能缺失等位基因携带者与非携带者。
主要发现
- 功能缺失等位基因携带者中,主要缺血事件发生率阿司匹林组6.7%对双联抗血小板组2.3%(HR 0.33,95%CI 0.09-1.21;P=0.09)。
- 非携带者中,主要缺血事件发生率阿司匹林组5.6%对双联抗血小板组3.7%(HR 0.65,95%CI 0.32-1.34;P=0.25)。
- 基因型与主要缺血事件的交互作用P=0.36,与卒中的交互作用P=0.33。
关键数值与推荐
- 主要缺血事件:携带者HR 0.33(95%CI 0.09-1.21;P=0.09),非携带者HR 0.65(95%CI 0.32-1.34;P=0.25)。
- 基因型与治疗组交互作用:主要缺血事件P=0.36,卒中P=0.33。
- 研究统计效能有限,仅50%。
临床怎么用
- 在POINT试验人群中,CYP2C19功能缺失携带状态未显著改变双联抗血小板治疗相对于阿司匹林的疗效。
- 不能依据本亚组结果常规以CYP2C19基因型决定急性轻型缺血性卒中/TIA的双联抗血小板治疗选择。
- CHANCE与POINT结果不一致,临床决策需结合种族构成及整体证据综合判断。
局限性
- 仅检测CYP2C19 *2、*3、*17等位基因,未覆盖其他可能相关变异。
- 为亚组分析,参与中心仅占POINT全部中心的134/269,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Clopidogrel is an antiplatelet drug that is metabolized to its active form by the CYP2C19 enzyme. The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) found a significant interaction between loss-of-function allele status for the CYP2C19 gene and the effect of dual antiplatelet therapy with aspirin and clopidogrel on the rate of early recurrent stroke following acute transient ischemic attack/minor stroke. The POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial), similar in design to CHANCE but performed largely in North America and Europe, demonstrated a reduction in early recurrent stroke with dual antiplatelet therapy compared with aspirin alone. This substudy was done to evaluate a potential interaction between loss-of-function CYP2C19 alleles and outcome by treatment group in POINT. METHODS: Of the 269 sites in 10 countries that enrolled patients in POINT, 134 sites participated in this substudy. DNA samples were genotyped for CYP2C19 *2, *3, and *17 alleles and classified as being carriers or noncarriers of loss-of-function alleles. Major ischemia consisted of ischemic stroke, myocardial infarction, or ischemic vascular death. RESULTS: Nine hundred thirty-two patients provided analyzable DNA. The rates of major ischemia were 6.7% for the aspirin group versus 2.3% for the dual antiplatelet therapy group (hazard ratio, 0.33 [95% CI, 0.09-1.21]; P=0.09) among carriers of loss-of-function allele. The rates of major ischemia were 5.6% for the aspirin group versus 3.7% for the dual antiplatelet therapy group (hazard ratio, 0.65 [95% CI, 0.32-1.34]; P=0.25) among noncarriers. There was no significant interaction by genotype for major ischemia (P=0.36) or stroke (P=0.33). CONCLUSIONS: This substudy of POINT found no significant interaction with CYP2C19 loss-of-function carrier status and outcome by treatment group. Failure to confirm the findings from the CHANCE trial may be because the loss-of-function alleles tested are not clinically important in this context or because the 2 trials had differences in racial/ethnic composition. Additionally, differences between the 2 trials might be due to chance as our statistical power was limited to 50%. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00991029.
引用
- Meschia JF, Walton RL, Farrugia LP, et al. Efficacy of Clopidogrel for Prevention of Stroke Based on CYP2C19 Allele Status in the POINT Trial. Stroke. 2020. PMID: 32568642. doi:10.1161/STROKEAHA.119.028713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。